Identification

Name
Clobetasone
Accession Number
DB13158
Type
Small Molecule
Groups
Approved
Description

Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Clobetasone butyrate8U0H6XI6EO25122-57-0FBRAWBYQGRLCEK-AVVSTMBFSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EumovateOintment0.05 %TopicalGlaxosmithkline Inc2001-06-252007-08-02Canada
Eumovate Ont 0.05%Ointment0.05 %TopicalGlaxo Canada Inc1979-12-312001-08-01Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eumovate Crm 0.05%Cream0.05 %TopicalGlaxo Canada Inc1979-12-312000-08-02Canada
Spectro Eczemacare Medicated CreamCream0.05 %TopicalGlaxosmithkline Inc1999-09-27Not applicableCanada
International/Other Brands
Eumosone (GlaxoSmithKline) / Eumovate (GlaxoSmithKline)
Categories
UNII
LT69WY1J6D
CAS number
54063-32-0
Weight
Average: 408.89
Monoisotopic: 408.1503652
Chemical Formula
C22H26ClFO4
InChI Key
XXIFVOHLGBURIG-OZCCCYNHSA-N
InChI
InChI=1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S)-14-(2-chloroacetyl)-1-fluoro-14-hydroxy-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
SMILES

Pharmacology

Indication

In dermatology, topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.

Structured Indications
Pharmacodynamics

Topical corticosteroid like clobetasone are synthetic derivatives of cortisone which produce anti-inflammatory, antiproliferative, immunosuppressive and vasoconstrictor effects when applied to the skin.

Mechanism of action

Topically applied clobeyasone are thought to bind with cytoplasmic receptors in the dermal and intradermal cells and to induce inhibitory proteins, thus leading to decreased activity of prostaglandins, kinins, histamine, liposomal enzymes and other endogenous mediators of inflammation. Topical corticosteroids inhibit the migration of macrophages and leukocytes into areas of inflamed skin by reversing vascular dilation and permeability, resulting in decreased erythema, edema and pruritus.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Absorption is dependent on many drug-related factors including: intrinsic properties of the steroid itself; concentration of the drug (increased concentration generally leads to more drug being absorbed but may plateau at higher concentrations); vehicle used (optimized or augmented vehicles > ointments or gels > creams or lotions); duration of exposure; frequency of application; combination with other products that break down the skin barrier and increase absorption (e.g., salicylic acid, urea). Patient-related factors that influence absorption include: patient age (infants and children absorb topical medications more quickly and to a greater degree than adults, and have a greater total skin surface to body weight ratio; the elderly have thinner skin and absorb drug more readily); disruption of the skin due to inflammation or disease (e.g., absorption increased in atopic dermatitis); total skin area treated; skin site treated (absorption is much greater from thin-skinned areas such as scalp, face, eyelid, axilla, and scrotum than from areas with thicker skin such as forearm, knee, elbow, palm and sole); absorption is increased with increased temperature or humidity of the skin or the environment; occlusion of the treated skin (via plastic wrap, oily vehicles, dressings, tape, diapers, tight-fitting clothing, etc.) can increase absorption up to 10-fold.

Volume of distribution

The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection.

Protein binding
Not Available
Metabolism

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolised, primarily in the liver.

Route of elimination

Clobetasone and its metabolites are excreted in urine.

Half life

N/A

Clearance
Not Available
Toxicity

Organism : Mouse Test type: LD50 Oral (Reported dose: >6gm/kg) LD50 Subcutaneous ( >3600mg/kg ) Effects : Behavioral : somnolence ( general depressed activity ) Blood changes in spleen

Organism : Mouse Test type: LD50 Route: Intraperitoneal Reported dose: 500 mg/kg

LD50 rat : 1510mg/kg Intraperitoneal LD50 rat >6gm/kg Oral LD 50 rat : > 2600mg/kg subcutaneous

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Clobetasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clobetasone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clobetasone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clobetasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Clobetasone.Approved, Withdrawn
AldesleukinClobetasone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Clobetasone can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Clobetasone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Clobetasone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clobetasone.Experimental
AloglutamolThe bioavailability of Clobetasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Clobetasone.Experimental
AluminiumThe bioavailability of Clobetasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Clobetasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Clobetasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Clobetasone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Clobetasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clobetasone.Approved
AmiodaroneThe serum concentration of Clobetasone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BClobetasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Clobetasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clobetasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Clobetasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clobetasone.Approved, Investigational
AprepitantThe serum concentration of Clobetasone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Clobetasone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Clobetasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Clobetasone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Clobetasone.Experimental
BendroflumethiazideClobetasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Clobetasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clobetasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clobetasone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Clobetasone.Experimental
Bismuth SubcitrateThe bioavailability of Clobetasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Clobetasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Clobetasone can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clobetasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Clobetasone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Clobetasone.Experimental
BumetanideClobetasone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Clobetasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Clobetasone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideClobetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Clobetasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Clobetasone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clobetasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasone.Approved, Investigational
CeritinibClobetasone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clobetasone.Approved, Vet Approved
ChlorothiazideClobetasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Clobetasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneClobetasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Clobetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Clobetasone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Clobetasone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clobetasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Clobetasone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Clobetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Clobetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Clobetasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clobetasone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Clobetasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Clobetasone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Clobetasone.Investigational
CyclopenthiazideClobetasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Clobetasone.Investigational
DaidzeinThe serum concentration of Clobetasone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Clobetasone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Clobetasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clobetasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Clobetasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Clobetasone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Clobetasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clobetasone.Approved, Vet Approved
DienestrolThe serum concentration of Clobetasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Clobetasone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Clobetasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasone.Approved
DihydrotestosteroneClobetasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Clobetasone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clobetasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Clobetasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Clobetasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Clobetasone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Clobetasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Clobetasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasone.Approved
EquolThe serum concentration of Clobetasone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Clobetasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Clobetasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clobetasone can be increased when it is combined with Estrone.Approved
Etacrynic acidClobetasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Clobetasone.Experimental
Ethinyl EstradiolThe serum concentration of Clobetasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clobetasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Clobetasone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Clobetasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Clobetasone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clobetasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Clobetasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Clobetasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Clobetasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clobetasone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clobetasone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Clobetasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Clobetasone.Experimental
FluoxymesteroneClobetasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clobetasone.Approved, Investigational
FosaprepitantThe serum concentration of Clobetasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Clobetasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideClobetasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Clobetasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Clobetasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Clobetasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Clobetasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Clobetasone is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Clobetasone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clobetasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Clobetasone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Clobetasone.Experimental
HexestrolThe serum concentration of Clobetasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Clobetasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Clobetasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasone.Approved, Investigational
HydrochlorothiazideClobetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideClobetasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Clobetasone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clobetasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clobetasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasone.Approved
IdelalisibThe serum concentration of Clobetasone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Clobetasone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Clobetasone.Approved
IndapamideClobetasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Clobetasone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Clobetasone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clobetasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Clobetasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Clobetasone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Clobetasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Clobetasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clobetasone.Withdrawn
ItraconazoleThe serum concentration of Clobetasone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clobetasone.Experimental
KetoconazoleThe serum concentration of Clobetasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clobetasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clobetasone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Clobetasone.Experimental
LopinavirThe serum concentration of Clobetasone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clobetasone.Approved
LumacaftorThe serum concentration of Clobetasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clobetasone.Approved, Investigational
MagaldrateThe bioavailability of Clobetasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Clobetasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Clobetasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Clobetasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasone.Approved
Magnesium silicateThe bioavailability of Clobetasone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Clobetasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Clobetasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clobetasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clobetasone.Approved
MesteroloneClobetasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Clobetasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasone.Withdrawn
MethallenestrilThe serum concentration of Clobetasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Clobetasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideClobetasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Clobetasone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneClobetasone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Clobetasone is combined with Metoclopramide.Approved, Investigational
MetolazoneClobetasone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Clobetasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Clobetasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Clobetasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Clobetasone.Experimental
MoxestrolThe serum concentration of Clobetasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clobetasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Clobetasone is combined with Nalidixic Acid.Approved
NandroloneClobetasone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasone.Approved, Vet Approved
NefazodoneThe serum concentration of Clobetasone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Clobetasone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clobetasone.Approved
NevirapineThe serum concentration of Clobetasone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Clobetasone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Clobetasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clobetasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Clobetasone.Vet Approved
OxandroloneClobetasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Clobetasone is combined with Oxolinic acid.Experimental
OxymetholoneClobetasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasone.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Clobetasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clobetasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Clobetasone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Clobetasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Clobetasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clobetasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Clobetasone.Approved, Investigational
PhenytoinThe serum concentration of Clobetasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Clobetasone is combined with Pipemidic acid.Experimental
PiretanideClobetasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Clobetasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Clobetasone.Experimental
Polyestradiol phosphateThe serum concentration of Clobetasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideClobetasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Clobetasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clobetasone.Experimental
PrimidoneThe serum concentration of Clobetasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Clobetasone.Experimental
PromestrieneThe serum concentration of Clobetasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clobetasone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Clobetasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Clobetasone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Clobetasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneClobetasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Clobetasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasone.Experimental, Investigational
RifabutinThe serum concentration of Clobetasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Clobetasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clobetasone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Clobetasone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clobetasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clobetasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasone.Approved
SaquinavirThe serum concentration of Clobetasone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Clobetasone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Clobetasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clobetasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clobetasone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Clobetasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clobetasone.Investigational
St. John's WortThe serum concentration of Clobetasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololClobetasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Clobetasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clobetasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Clobetasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Clobetasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Clobetasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clobetasone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Clobetasone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Clobetasone.Withdrawn
TelithromycinThe serum concentration of Clobetasone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Clobetasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clobetasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Clobetasone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clobetasone.Approved
TestosteroneClobetasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Clobetasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasone.Approved
TiboloneThe serum concentration of Clobetasone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clobetasone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasone.Approved
TorasemideClobetasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Clobetasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Clobetasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideClobetasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Clobetasone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Clobetasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Clobetasone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinClobetasone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasone.Approved
ZeranolThe serum concentration of Clobetasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clobetasone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Clobetasone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. Medsafe [Link]
  3. ChemIdplus [Link]
External Links
KEGG Drug
D07717
ChemSpider
64482
Wikipedia
Clobetasone
ATC Codes
S01BA09 — ClobetasoneD07AB01 — ClobetasoneS01CA11 — Clobetasone and antiinfectives
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentDermatitis, Eczematous1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
OintmentTopical0.05 %
CreamTopical0.05 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00691 mg/mLALOGPS
logP2.88ALOGPS
logP3.6ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)12.49ChemAxon
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.44 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity104.72 m3·mol-1ChemAxon
Polarizability41.36 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-oxosteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Alpha-chloroketones / Cyclic ketones
show 7 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Halo-steroid / 17-hydroxysteroid / Hydroxysteroid / Oxosteroid / 11-oxosteroid
show 21 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. UniProt [Link]
  2. KEGG [Link]

Drug created on December 04, 2016 20:58 / Updated on October 21, 2017 19:35